712 related articles for article (PubMed ID: 33309581)
1. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
2. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
3. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Chen F; Tian G; Bai X; Li J; Yuan Z
Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
[TBL] [Abstract][Full Text] [Related]
4. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Eur J Heart Fail; 2020 Nov; 22(11):2018-2025. PubMed ID: 32946164
[TBL] [Abstract][Full Text] [Related]
5. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
[TBL] [Abstract][Full Text] [Related]
6. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
[TBL] [Abstract][Full Text] [Related]
7. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Camacho A; Iyer SR; Maisel AS; Felker GM; Butler J; Piña IL; Ibrahim NE; Abbas C; Burnett JC; Solomon SD; Januzzi JL
JACC Heart Fail; 2021 Feb; 9(2):127-136. PubMed ID: 33189632
[TBL] [Abstract][Full Text] [Related]
8. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
10. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
[TBL] [Abstract][Full Text] [Related]
11. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
12. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
13. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
14. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
15. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
17. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
19. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
[TBL] [Abstract][Full Text] [Related]
20. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]